Compare CDNA & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDNA | EOS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2014 | N/A |
| Metric | CDNA | EOS |
|---|---|---|
| Price | $19.44 | $21.80 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 656.6K | 84.1K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.80% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $357,998,000.00 | N/A |
| Revenue This Year | $14.49 | N/A |
| Revenue Next Year | $11.32 | N/A |
| P/E Ratio | $16.16 | ★ N/A |
| Revenue Growth | ★ 14.46 | N/A |
| 52 Week Low | $10.96 | $15.62 |
| 52 Week High | $25.55 | $20.63 |
| Indicator | CDNA | EOS |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 36.37 |
| Support Level | $18.81 | $21.57 |
| Resistance Level | $21.00 | $22.50 |
| Average True Range (ATR) | 1.11 | 0.33 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 40.03 | 21.03 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.